These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8167604)

  • 41. Meningitis vaccination in Auckland.
    Ellis-Pegler RB
    N Z Med J; 1987 Aug; 100(829):501. PubMed ID: 3455518
    [No Abstract]   [Full Text] [Related]  

  • 42. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.
    Brooks R; Woods CW; Benjamin DK; Rosenstein NE
    Clin Infect Dis; 2006 Jul; 43(1):49-54. PubMed ID: 16758417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
    de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Control of meningococcal disease: guidance for microbiologists: CCDC. Consultant in Communicable Disease Control, England.
    Kaczmarski EB; Cartwright KA
    Commun Dis Rep CDR Rev; 1995 Dec; 5(13):R196-8. PubMed ID: 8556103
    [No Abstract]   [Full Text] [Related]  

  • 45. Development of the epidemiological situation in invasive meningococcal disease in the Czech Republic caused by emerging Neisseria meningitidis clone ET-15/37.
    Krízová P; Musílek M; Kalmusová J
    Cent Eur J Public Health; 1997 Dec; 5(4):214-8. PubMed ID: 9457424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Nov; 33(ACS-11):1-12. PubMed ID: 18064747
    [No Abstract]   [Full Text] [Related]  

  • 47. [Control of a school outbreak of serogroup B meningococcal disease by chemoprophylaxis with azithromycin and ciprofloxacin].
    González de Aledo Linos A; García Merino J
    An Esp Pediatr; 2000 Nov; 53(5):412-7. PubMed ID: 11521657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
    O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D
    Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Susceptibility to antimicrobial drugs used in the prophylaxis of meningococcal disease: situation after an epidemic wave].
    Arreaza L; de la Fuente L; Fernández S; Vázquez JA
    Rev Esp Quimioter; 2000 Jun; 13(2):182-6. PubMed ID: 10918092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
    Dyet K; Devoy A; McDowell R; Martin D
    Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
    Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
    Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario.
    Khalil MK; Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):231-4. PubMed ID: 19717106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].
    de Vries M; Dankert J; Ruijs H; Timen A; de Greeff S; de Melker H
    Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1562-3. PubMed ID: 12212505
    [No Abstract]   [Full Text] [Related]  

  • 54. Quarterly Communicable Disease Review January to March 1997. From the PHLS Communicable Disease Surveillance Unit.
    Hamilton G; Catchpole M; Bartlett CL; Lane C; Joseph C; Duckworth G
    J Public Health Med; 1997 Sep; 19(3):354-9. PubMed ID: 9347463
    [No Abstract]   [Full Text] [Related]  

  • 55. Preventing meningococcal outbreaks: an opportunity for pharmacists.
    Marquess JG
    J Am Pharm Assoc (Wash); 2003; 43(1):114-5. PubMed ID: 12585760
    [No Abstract]   [Full Text] [Related]  

  • 56. Traveling with children.
    Katz BZ
    Pediatr Infect Dis J; 2003 Mar; 22(3):274-6. PubMed ID: 12634592
    [No Abstract]   [Full Text] [Related]  

  • 57. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meningococcal disease: risk for international travellers and vaccine strategies.
    Wilder-Smith A
    Travel Med Infect Dis; 2008 Jul; 6(4):182-6. PubMed ID: 18571105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Control of meningococcal disease.
    Begg NT
    Commun Dis Rep CDR Rev; 1992 May; 2(6):R65. PubMed ID: 1285108
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of single dose ceftriaxone in the emergency department during an outbreak of serogroup C meningococcal disease.
    Banerji A; King WJ; MacDonald N; Li M
    Pediatr Infect Dis J; 1995 Oct; 14(10):904-5. PubMed ID: 8584321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.